- Quantum Leap Healthcare, the sponsor of the I-SPY COVID Trial, said it will not proceed with further testing of Aerpio Pharmaceuticals (NASDAQ:ARPO) drug, razuprotafib, in reducing the risk of death from and severity of illness for people who become critically ill after contracting COVID-19.
- Quantum halted testing of Aerpio’s razuprotafib in the trial because it was challenging to administer in the setting of COVID-19, with 30% of patients discontinuing due to disease-related hypotension, including protocol-mandated stopping rules.
- There was no indication that razuprotafib caused the hypotension that led to clinical decline in systolic blood pressure.
- The purpose of the I-SPY trial is to rapidly screen multiple agents to find those with the best chance of effectively improving outcomes for those critically ill.